TABLE 4.
New action taken for management of heavy or prolonged menstrual bleeding during study treatment
| Actions |
Rivaroxaban 20 mg n = 134 |
Rivaroxaban 10 mg n = 120 |
Aspirin n = 108 |
|---|---|---|---|
| Patients with any action, n (%) | 21 (15.7) | 15 (12.5) | 15 (13.9) |
| Change in hormonal therapy | 9 (6.7) | 9 (7.5) | 8 (7.4) |
| Stop or interruption of study medication | 6 (4.5) | 2 (1.7) | 2 (1.9) |
| Referral to gynecologist | 4 (3.0) | 4 (3.3) | 4 (3.7) |
| Blood transfusion | 2 (1.5) | 0 | 0 |
| Prohemostatic/antifibrinolytic therapy | 1 (0.7) a | 0 | 0 |
| Iron supplementation | 0 | 1 (0.8) | 1 (0.9) |
a
Tranexamic acid.